BMS-833923 CAS NO.1059734-66-5

1.we are direct manufacturer and we have 7 years experience in this aera.
2.we can provide competitive price for every customer and guarantee the quality of our goods.
3.Specials are possible when client's order is big enough, including the discount policy;
4.we promise we will return your money if our product don't have effect.
5.Our company promise to deliver clients' package to his hands safely, or we'll cover the total loss and reship in time;
6. Our customers may buy our products again after they use our sample.

In stock ,>98% purity with low price. If you need HNMR\HPLC,please contact us!

 BMS-833923, also known as XL-139, is an orally bioavailable small-molecule SMO (Smoothened) inhibitor with potential antineoplastic activity. SMO antagonist BMS-833923 inhibits the sonic hedgehog (SHH) pathway protein SMO, which may result in a suppression of the SHH signaling pathway. SMO is a G-protein coupled receptor that lies just downstream of the SHH ligand cell surface receptor Patched-1 in the SHH pathway; in the absence of ligand Patched-1 inhibits SMO and ligand binding to Patched-1 results in increased levels of SMO. The SHH signaling pathway plays an important role in cellular growth, differentiation and repair; constitutive activation of this pathway is associated with uncontrolled cellular proliferation and has been observed in a variety of cancers. Check for active clinical trials or closed clinical trials using this agent.

Tianjin Kailiqi Biopharma Technology Co., Ltd, is a professional manufacturer specialized in the production and distribution of active pharmaceutical ingredients and intermediates. Our company has strong R&D ability and production experience to provide the customers new APIs. We specialize in developing innovative processes for the synthesis of a wide range of products. We also undertake custom synthesis and contract manufacturing.if you are interest in,pls contact with me,we also have Lab,specifical in some hard synthesis.